← SynDRA
LY-2334737
SynDRA canonical compound SYN0020179 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Mechanism of action | antitumor agent | ribonucleotide reductase inhibitor |
All known targets
Mechanisms of action (all sources)
- antitumor agent
- ribonucleotide reductase inhibitor
- RRM2 MODULATOR
Cross-references
Synonyms
- LY2334737
- Gem prodrug (cancer), Eli Lilly
- Gemcitabine prodrug (cancer), Lilly
- LY 2334737
- Cytidine, 2'-deoxy-2',2'-difluoro-N-(1-oxo-2-propylpentyl)-
- YLR364XYSA
- N-[1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]-2-propylpentanamide
- UNII-YLR364XYSA
- SCHEMBL595762
- CHEMBL577711
- DTXSID001025742
- ZINC35996916
- BL98401
- CS-1815
- DB12906
- NCGC00378563-01
- NCGC00378563-02
- HY-13672
- LY 2334737;LY-2334737
- Q27294578
- 2'-Deoxy-2',2'-difluoro-N-(1-oxo-2-propylpentyl)-cytidine
- 1-(2,2-difluoro-2-deoxy-beta-D-ribofuranosyl)-4-(2-propyl-1-oxopentyl)aminopyrimidin-2-one
- RefChem:154538
- Gemcitabine Prodrug LY2334737
- 2'-Deoxy-2',2'-difluoro-N-(1-oxo-2-propylpentyl)cytidine
- orb1303216
- C17H25F2N3O5
- JXRHGMJVKRFLOK-UXIGCNINSA-N
- GLXC-90429
- EX-A8467
- AKOS030526967
- DA-65141
- MS-26471
- NS00072176
- T4061
- BRD-K04993719-001-01-7
Look up LY-2334737 in the interactive SynDRA portal →